D.E. Shaw & Co
AMRI

D.E. Shaw & Co’s Albany Molecular Research Inc AMRI Stock Holding History

D.E. Shaw & Co’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-35,200
Closed -$573K – 4218
2014
Q4 		$573K Sell
35,200
-11,500
-25% -$211K ﹤0.01% 3226
2014
Q3 		$1.03M Sell
46,700
-69,200
-60% -$1.42M ﹤0.01% 2787
2014
Q2 		$2.33M Buy
115,900
+35,200
+44% +$596K ﹤0.01% 2191
2014
Q1 		$1.5M Buy
+80,700
New +$1.11M ﹤0.01% 2663

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

D.E. Shaw & Co's AMRI Position: Q3 2017 in Review

D.E. Shaw & Co sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 318,662 shares — an estimated $6.92M sold.

D.E. Shaw & Co first reported a position in AMRI in Q2 2013 and held it in 11 quarters. The position peaked at $6.92M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • D.E. Shaw & Co reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 318,662 Albany Molecular Research Inc shares in Q3 2017, an estimated $6.92M.
  • D.E. Shaw & Co first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 11 quarters.
  • D.E. Shaw & Co's Albany Molecular Research Inc position peaked at $6.92M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.